Abstract
Medical and scientific research in the field of pulmonary arterial hypertension (PAH) in adults with congenital heart disease (ACHD) in the past few years has gradually become globalized, inclusive and collaborative. Education of physicians, health administrators and patients in congenital heart disease (CHD), especially in the field of PAH, is of paramount importance. It is also crucial for ACHD patients with PAH to be followed in tertiary centres where they can benefit from a multidisciplinary approach. Shared care models dictate closer collaboration between tertiary expert centres and local non-specialist services, as well as networking between CHD and PAH physicians and geneticists/epidemiologists, with inclusion of PAH–CHD patients in national and international registries, and detailed genotypic/phenotypic characterization.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- ACHD:
-
Adult congenital heart disease
- CHD:
-
Congenital heart disease
- PAH:
-
Pulmonary arterial hypertension
References
Kempny A, Fernández-Jiménez R, Tutarel O, Dimopoulos K, Uebing A, Shiina Y et al (2013) Meeting the challenge: the evolving global landscape of adult congenital heart disease. Int J Cardiol 168(6):5182–5189
Gatzoulis MA, Beghetti M, Landzberg MJ, Galiè N (2014) Pulmonary arterial hypertension associated with congenital heart disease: recent advances and future directions. Int J Cardiol 177(2):340–347
Gatzoulis MA, Alonso-Gonzalez R, Beghetti M (2009) Pulmonary arterial hypertension in paediatric and adult patients with congenital heart disease. Eur Respir Rev 18(113):154–161
Ivy DD, Abman SH, Barst RJ, Berger RM, Bonnet D, Fleming TR et al (2013) Pediatric pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D117–D126
Dimopoulos K, Wort SJ, Gatzoulis MA (2014) Pulmonary hypertension related to congenital heart disease: a call for action. Eur Heart J 35(11):691–700
Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A et al (2013) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D34–D41
Dimopoulos K, Peset A, Gatzoulis MA (2008) Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy. Int J Cardiol 129(2):163–171
Dimopoulos K, Giannakoulas G, Wort SJ, Gatzoulis MA (2008) Pulmonary arterial hypertension in adults with congenital heart disease: distinct differences from other causes of pulmonary arterial hypertension and management implications. Curr Opin Cardiol 23(6):545–554
Diller GP, Kempny A, Inuzuka R, Radke R, Wort SJ, Baumgartner H et al (2014) Survival prospects of treatment naïve patients with Eisenmenger: a systematic review of the literature and report of own experience. Heart 100(17):1366–1372
Manes A, Palazzini M, Leci E, Bacchi Reggiani ML, Branzi A, Galiè N (2014) Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J 35(11):716–724
Dimopoulos K, Inuzuka R, Goletto S, Giannakoulas G, Swan L, Wort SJ et al (2010) Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 121(1):20–25
Schuuring MJ, Bouma BJ, Cordina R, Gatzoulis MA, Budts W, Mullen MP et al (2013) Treatment of segmental pulmonary artery hypertension in adults with congenital heart disease. Int J Cardiol 164(1):106–110
Giannakoulas G, Boutsikou M (2015) The Gordian knot of thromboembolism in congenital heart disease. Heart 101(19):1523–1524
Giannakoulas G, Dimopoulos K (2010) Exercise training in congenital heart disease: should we follow the heart failure paradigm? Int J Cardiol 138(2):109–111
Dimopoulos K (2008) Trials and tribulations in adult congenital heart disease. Int J Cardiol 129:160–162
Giannakoulas G, Mouratoglou SA, Gatzoulis MA, Karvounis H (2014) Blood biomarkers and their potential role in pulmonary arterial hypertension associated with congenital heart disease. A systematic review. Int J Cardiol 174(3):618–623
Hebert A, Mikkelsen UR, Thilen U, Idorn L, Jensen AS, Nagy E et al (2014) Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (Treatment With Endothelin Receptor Antagonist in Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen Consumption) study. Circulation 130(23):2021–2030
Diller GP, Kempny A, Piorkowski A, Grübler M, Swan L, Baumgartner H et al (2014) Choice and competition between adult congenital heart disease centers: evidence of considerable geographical disparities and association with clinical or academic results. Circ Cardiovasc Qual Outcomes 7(2):285–291
Gatzoulis MA (2006) Adult congenital heart disease: education, education, education. Nat Clin Pract Cardiovasc Med 3(1):2–3
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Giannakoulas, G., Gatzoulis, M.A. (2017). PAH in ACHD: Research, Global Perspective and Future Prospects. An Epilogue. In: Dimopoulos, K., Diller, GP. (eds) Pulmonary Hypertension in Adult Congenital Heart Disease. Congenital Heart Disease in Adolescents and Adults. Springer, Cham. https://doi.org/10.1007/978-3-319-46028-4_24
Download citation
DOI: https://doi.org/10.1007/978-3-319-46028-4_24
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-46026-0
Online ISBN: 978-3-319-46028-4
eBook Packages: MedicineMedicine (R0)